<DOC>
	<DOC>NCT02538107</DOC>
	<brief_summary>This observational study will investigate efficacy and safety of methoxy polyethyleneglycol-epoetin beta in participants with a kidney transplant. Data of each participant will be collected over 15 months of Mircera therapy.</brief_summary>
	<brief_title>An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant</brief_title>
	<detailed_description />
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Participants with kidney transplant and a chronic kidney disease (CKD), who need erythropoiesis stimulating agent (ESA) therapy as part of their medical care and prescribed methoxy polyethyleneglycolepoetin beta by the doctor. The transplant should function regularly and without need of continuous dialysis treatment at inclusion and also during the documentation period of this study according to treating physician's prognosis. Kidney transplantation dates back less than 3 months. Acute decrease of hemoglobin (Hb) before enrollment, defined as decrease of greater than or equal to (&gt;/=) 2 g/dL between two sequential values. Administration of other ESA therapies during the observation period.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>